Anti-glycan antibodies: roles in human disease

Biochem J. 2021 Apr 30;478(8):1485-1509. doi: 10.1042/BCJ20200610.

Abstract

Carbohydrate-binding antibodies play diverse and critical roles in human health. Endogenous carbohydrate-binding antibodies that recognize bacterial, fungal, and other microbial carbohydrates prevent systemic infections and help maintain microbiome homeostasis. Anti-glycan antibodies can have both beneficial and detrimental effects. For example, alloantibodies to ABO blood group carbohydrates can help reduce the spread of some infectious diseases, but they also impose limitations for blood transfusions. Antibodies that recognize self-glycans can contribute to autoimmune diseases, such as Guillain-Barre syndrome. In addition to endogenous antibodies that arise through natural processes, a variety of vaccines induce anti-glycan antibodies as a primary mechanism of protection. Some examples of approved carbohydrate-based vaccines that have had a major impact on human health are against pneumococcus, Haemophilus influeanza type b, and Neisseria meningitidis. Monoclonal antibodies specifically targeting pathogen associated or tumor associated carbohydrate antigens (TACAs) are used clinically for both diagnostic and therapeutic purposes. This review aims to highlight some of the well-studied and critically important applications of anti-carbohydrate antibodies.

Keywords: antibodies; antigens; autoimmunity; cancer; glycobiology.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / biosynthesis
  • Antibodies, Monoclonal / therapeutic use
  • Autoantibodies / biosynthesis
  • Autoantibodies / blood
  • Bacterial Vaccines / biosynthesis
  • Bacterial Vaccines / therapeutic use
  • Carbohydrate Sequence
  • Guillain-Barre Syndrome / immunology*
  • Guillain-Barre Syndrome / pathology
  • Haemophilus Infections / immunology*
  • Haemophilus Infections / microbiology
  • Haemophilus Infections / prevention & control
  • Haemophilus Vaccines / biosynthesis
  • Haemophilus Vaccines / therapeutic use
  • Haemophilus influenzae / immunology
  • Humans
  • Meningitis, Meningococcal / immunology*
  • Meningitis, Meningococcal / microbiology
  • Meningitis, Meningococcal / prevention & control
  • Neisseria meningitidis / immunology
  • Pneumococcal Vaccines / biosynthesis
  • Pneumococcal Vaccines / therapeutic use
  • Pneumonia, Pneumococcal / immunology*
  • Pneumonia, Pneumococcal / microbiology
  • Pneumonia, Pneumococcal / prevention & control
  • Polysaccharides / antagonists & inhibitors
  • Polysaccharides / chemistry
  • Polysaccharides / immunology*
  • Streptococcus pneumoniae / immunology

Substances

  • Antibodies, Monoclonal
  • Autoantibodies
  • Bacterial Vaccines
  • Haemophilus Vaccines
  • Pneumococcal Vaccines
  • Polysaccharides